Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Readystate Asset Management LP

Readystate Asset Management LP lowered its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 96.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,603 shares of the company's stock after selling 109,220 shares during the quarter. Readystate Asset Management LP's holdings in Keros Therapeutics were worth $267,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after buying an additional 280 shares during the last quarter. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company's stock valued at $223,000 after acquiring an additional 1,033 shares in the last quarter. Arizona State Retirement System grew its stake in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock worth $369,000 after purchasing an additional 1,130 shares during the period. Finally, Algert Global LLC grew its position in shares of Keros Therapeutics by 10.6% in the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company's stock worth $717,000 after buying an additional 1,505 shares during the period. Institutional investors own 71.56% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Guggenheim reiterated a "buy" rating and set a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday. Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $89.56.

Keros Therapeutics Trading Up 8.3 %

Shares of KROS traded up $5.39 during mid-day trading on Friday, hitting $70.00. The company's stock had a trading volume of 485,950 shares, compared to its average volume of 376,835. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -13.44 and a beta of 1.20. Keros Therapeutics, Inc. has a 52-week low of $27.31 and a 52-week high of $73.00. The company's 50-day moving average is $60.05 and its 200-day moving average is $52.56.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm's quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the business posted ($1.33) EPS. As a group, sell-side analysts predict that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.